000 03377nam a22003735i 4500
001 290523
003 MX-SnUAN
005 20160429154750.0
007 cr nn 008mamaa
008 150903s2013 xxu| o |||| 0|eng d
020 _a9781461476542
_99781461476542
024 7 _a10.1007/9781461476542
_2doi
035 _avtls000342259
039 9 _a201509030850
_bVLOAD
_c201405050241
_dVLOAD
_y201402061122
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC261-271
100 1 _aBonavida, Benjamin.
_eeditor.
_9314877
245 1 0 _aResistance to Immunotherapeutic Antibodies in Cancer :
_bStrategies to Overcome Resistance /
_cedited by Benjamin Bonavida.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2013.
300 _axiii, 202 páginas 29 ilustraciones, 15 ilustraciones en color.
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v2
500 _aSpringer eBooks
505 0 _aPreface -- Introduction and generation of chimeric and humanized mAbs -- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment -- Antibodies directed against different major cancers: Effects when used  alone or in combination with drugs -- Mechanisms of antibodies-mediated responses, in vitro and in vivo -- Molecular Pathways -- Molecular Signatures -- Identification of resistance targets for intervention -- Various chemicals that can sensitize resistant tumor cells -- Other mAbs -- Proteasome inhibitors -- Divalent mAbs -- Antibodies coupled to chemical inhibitors -- Antibodies coupled to cytokines -- Nanoparticles with mAbs -- Index.
520 _aThe current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9781461476535
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4614-7654-2
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c290523
_d290523